Chine Pharmaceutical Clinical Trial Regulations Reviewed in Discounted Access China Management Consulting Report Now Available at MarketPublishers.com26 Mar 2015 • by Natalie Aster
LONDON - One of the fastest growing economies on a global scale, China is also one of the largest healthcare markets, with its annual growth being 1 percent on average over the past few decades. As a result, the total value of the drugs segment amounted to almost USD 215 billion by 2014 and USD 250 billion by 2015. Currently, drugs produced by overseas or multinational pharmaceutical players hold a 25 percent share of the market. This share is expected to increase in the upcoming years since the country is set to the second largest drugs market after the USA thus becoming more attractive for foreign companies.
At present, regulations related to pharmaceutical clinical trials are going through drastic changes in the country. Overseas players have already started to experience the first results of the regulation enforcement. The country officially issued guidance on international multi-center clinical trials of drugs in the country which became effective in March 2015. This guidance is aimed at reducing risk related to examination uncertainty and approval delays.
Discounted research study “Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China” prepared by Access China Management Consulting Ltd. offers a detailed overview of China’s pharmaceutical market and examination of latest local regulations in this space. The report contains a thorough discussion of local regulatory authorities. It describes a background of the latest regulations, their applicable scope and general requirements related to international multi-center clinical trials of drugs in the country. The study sheds light on scientific and compliance issues that overseas players must consider. It includes practical guidance and canvasses opportunities of international multi-center clinical trials in the country.
Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials in China
Published: March, 2015
Price: US$ 1,495.00 US$ 1,270.00
Please note that the discount is available until April 19, 2015!
More new and discounted reports by the publisher can be found at Access China Management Consulting page.